Page 60 - 2020_11-Haematologica-web

A. Li et al.
Immunol. 2002;2(4):251-262.
11. Reshef R, Luger SM, Hexner EO, et al.
Blockade of lymphocyte chemotaxis in vis- ceral graft-versus-host disease. N Engl J Med. 2012;367(2):135-145.
12. Palucka K, Banchereau J. Dendritic-cell- based therapeutic cancer vaccines. Immunity. 2013;39(1):38-48.
13. Sandy AR, Chung J, Toubai T, et al. T cell- specific notch inhibition blocks graft-versus- host disease by inducing a hyporesponsive program in alloreactive CD4+ and CD8+ T cells. J Immunol. 2013;190(11):5818-5828.
14. Amsen D, Antov A, Flavell RA. The differ- ent faces of Notch in T-helper-cell differenti- ation. Nat Rev Immunol. 2009;9(2):116-124.
15.Tran IT, Sandy AR, Carulli AJ, et al. Blockade of individual Notch ligands and receptors controls graft-versus-host disease. J Clin Invest. 2013;123(4):1590-1604.
16. Baylin SB, Jones PA. Epigenetic Determi- nants of Cancer. Cold Spring Harb Perspect Biol. 2016;8(9):a019505.
17. Jones SC, Murphy GF, Friedman TM, Korngold R. Importance of minor histocom- patibility antigen expression by non- hematopoietic tissues in a CD4+ T cell- mediated graft-versus-host disease model. J Clin Invest. 2003;112(12):1880-1886.
18. Villagra A, Cheng F, Wang HW, et al. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol. 2009;10 (1):92-100.
19. Cheng F, Lienlaf M, Wang HW, et al. A novel role for histone deacetylase 6 in the regula- tion of the tolerogenic STAT3/IL-10 path- way in APCs. J Immunol. 2014;193(6):2850- 2862.
20. Reddy P, Sun Y, Toubai T, et al. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest. 2008;118(7):2562-2573.
21. Ni X, Song Q, Cassady K, et al. PD-L1 inter- acts with CD80 to regulate graft-versus- leukemia activity of donor CD8+ T cells. J Clin Invest. 2017;127(5):1960-1977.
22. Lee DY, Hayes JJ, Pruss D, Wolffe AP. A pos- itive role for histone acetylation in transcrip- tion factor access to nucleosomal DNA. Cell. 1993;72(1):73-84.
23. Reddy P, Maeda Y, Hotary K, et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus- host disease and preserves graft-versus- leukemia effect. Proc Natl Acad Sci U S A. 2004;101(11):3921-3926.
24. Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature. 2011;469(7330):343-349.
25. Jacob E, Hod-Dvorai R, Ben-Mordechai OL, Boyko Y, Avni O. Dual function of poly- comb group proteins in differentiated murine T helper (CD4+) cells. J Mol Signal. 2011;6:5.
26. Kamminga LM, Bystrykh LV, de Boer A, et al. The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood. 2006;107(5):2170-2179.
27. Tong Q, He S, Xie F, et al. Ezh2 Regulates transcriptional and posttranslational expres- sion of T-bet and promotes Th1 cell respons- es mediating aplastic anemia in mice. J Immunol. 2014;192(11):5012-5022.
28. He S, Xie F, Liu Y, et al. The histone methyl- transferase Ezh2 is a crucial epigenetic regu- lator of allogeneic T cell responses mediating graft-versus-host disease. Blood. 2013;122 (25):4119-4128.
29. Kato K, Cui S, Kuick R, et al. Identification of stem cell transcriptional programs nor- mally expressed in embryonic and neural stem cells in alloreactive CD8+ T cells mediating graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16(6):751- 771.
30. He S, Wang J, Kato K, et al. Inhibition of his- tone methylation arrests ongoing graft-ver- sus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. Blood. 2012;119(5):1274-1282.
31. Tumes DJ, Onodera A, Suzuki A, et al. The polycomb protein Ezh2 regulates differenti- ation and plasticity of CD4(+) T helper type 1 and type 2 cells. Immunity. 2013;39(5): 819-832.
32. He S, Liu Y, Meng L, et al. Ezh2 phosphory- lation state determines its capacity to main- tain CD8(+) T memory precursors for anti- tumor immunity. Nat Commun. 2017;8(1): 2125.
33. Huang Q, He S, Tian Y, et al. Hsp90 inhibi- tion destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice. Blood. 2017;129(20):2737-2748.
34. Li N, Zhao D, Kirschbaum M, et al. HDAC inhibitor reduces cytokine storm and facili- tates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen. Proc Natl Acad Sci U S A. 2008;105(12): 4796-4801.
35. Grausenburger R, Bilic I, Boucheron N, et al. Conditional deletion of histone deacetylase 1 in T cells leads to enhanced airway inflam- mation and increased Th2 cytokine produc- tion. J Immunol. 2010;185(6):3489-3497.
36. Woods DM, Woan KV, Cheng F, et al. T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactiv- ity in a murine model. Blood. 2017;130(2): 146-155.
37.de Zoeten EF, Wang L, Butler K, et al. Histone deacetylase 6 and heat shock pro- tein 90 control the functions of Foxp3(+) T- regulatory cells. Mol Cell Biol. 2011;31(10): 2066-2078.
38. Tsuji G, Okiyama N, Villarroel VA, Katz SI. Histone deacetylase 6 inhibition impairs effector CD8 T-cell functions during skin inflammation. J Allergy Clin Immunol. 2015;135(5):1228-1239.
39. Hirschey MD, Shimazu T, Goetzman E, et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetyla- tion. Nature. 2010;464(7285):121-125.
40.Toubai T, Tamaki H, Peltier DC, et al. Mitochondrial deacetylase SIRT3 plays an important role in donor T cell responses after experimental allogeneic hematopoietic Transplantation. J Immunol. 2018;201(11): 3443-3455.
41. Bestor TH. The DNA methyltransferases of mammals. Hum Mol Genet. 2000;9(16): 2395-2402.
42. Sanchez-Abarca LI, Gutierrez-Cosio S, Santamaria C, et al. Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood. 2010;115(1):107-121.
43. Ehx G, Fransolet G, de Leval L, et al. Azacytidine prevents experimental xeno- geneic graft-versus-host disease without abrogating graft-versus-leukemia effects. Oncoimmunology. 2017;6(5):e1314425.
44.Youngblood B, Hale JS, Kissick HT, et al. Effector CD8 T cells dedifferentiate into long-lived memory cells. Nature. 2017;552 (7685):404-409.
45. Anderson BE, McNiff J, Yan J, et al. Memory CD4+ T cells do not induce graft-versus-
host disease. J Clin Invest. 2003;112(1):101-
108.
46. Masopust D, Kaech SM, Wherry EJ, Ahmed
R. The role of programming in memory T- cell development. Curr Opin Immunol. 2004;16(2):217-225.
47.Wu Z, Bensinger SJ, Zhang J, et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med. 2004;10(1):87-92.
48. Maltzman JS, Turka LA. T-cell costimulatory blockade in organ transplantation. Cold Spring Harbor Perspect Med. 2013;3(12): a015537.
49. Pace L, Goudot C, Zueva E, et al. The epige- netic control of stemness in CD8(+) T cell fate commitment. Science. 2018;359(6372): 177-186.
50. Yamashita M, Hirahara K, Shinnakasu R, et al. Crucial role of MLL for the maintenance of memory T helper type 2 cell responses. Immunity. 2006;24(5):611-622.
51. Webb LM, Amici SA, Jablonski KA, et al. PRMT5-selective inhibitors suppress inflam- matory T cell responses and experimental autoimmune encephalomyelitis. J Immunol. 2017;198(4):1439-1451.
52. Negrin RS. Graft-versus-host disease versus graft-versus-leukemia. Hematology. 2015; 2015(1):225-230.
53. Ohkura N, Hamaguchi M, Morikawa H, et al. T cell receptor stimulation-induced epige- netic changes and Foxp3 expression are independent and complementary events required for Treg cell development. Immunity. 2012;37(5):785-799.
54. Workman CJ, Szymczak-Workman AL, Collison LW, Pillai MR, Vignali DA. The development and function of regulatory T cells. Cell Mol Life Sci. 2009;66(16):2603- 2622.
55. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med. 2002;196(3):401-406.
56. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical trans- plantation. Blood. 2011;117(14):3921-3928.
57. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99(10):3493-3499.
58. Hippen KL, Merkel SC, Schirm DK, et al. Generation and large-scale expansion of human inducible regulatory T cells that sup- press graft-versus-host disease. Am J Transplant. 2011;11(6):1148-1157.
59. Li J, Heinrichs J, Haarberg K, et al. HY- Specific induced regulatory T cells display high specificity and efficacy in the preven- tion of acute graft-versus-host disease. J Immunol. 2015;195(2):717-725.
60. Tang Q, Henriksen KJ, Bi M, et al. In vitro- expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med. 2004;199(11):1455-1465.
61. Zhou X, Bailey-Bucktrout SL, Jeker LT, et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic mem- ory T cells in vivo. Nat Immunol. 2009;10(9):1000-1007.
62.Koenecke C, Czeloth N, Bubke A, et al. Alloantigen-specific de novo-induced Foxp3+ Treg revert in vivo and do not pro- tect from experimental GVHD. Eur J Immunol. 2009;39(11):3091-3096.
63. Beres A, Komorowski R, Mihara M, Drobyski WR. Instability of Foxp3 expres-
2548
haematologica | 2020; 105(11)